Indications and administration of sparsentan

Sparsentan (also known as sparsentan, trade nameFilspari), as a treatment drug for specific kidney diseases, has attracted widespread attention around the world. This article will introduce in detail the indications and correct medication methods of sparsentane to help patients better understand and use this drug.

1. Indications of sparsentine

Sparsentan is mainly used to treat adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression and whose urine protein to creatinine ratio (UPCR) is ≥1.5g/g. It reduces the activity of two key mediators associated with the progression of IgA nephropathy by inhibiting endothelin A (ETA) receptors and angiotensin II subtype 1 (AT1) receptors, thereby reducing proteinuria levels and protecting kidney function.

2. How to use sparsentan

1. Dosage adjustment:

1) When starting treatment, the recommended dose is 200 milligrams (mg) once daily. After 14 days, the dose can be gradually increased to 400 milligrams (mg) once daily based on the patient's tolerance.

2) If treatment is interrupted for any reason, restarting should start with a dose of 200 mg once daily and adjust to 400 mg once daily after 14 days based on tolerance.

2. Medication time:

1) Sparsentane should be swallowed whole with water before breakfast or dinner to ensure effective absorption of the drug.

2) It is recommended that patients maintain the same dosing pattern with meals to form a stable medication habit.

3. Treatment of missed doses:

If a patient misses a dose, he or she should continue taking it at the next scheduled dose time and should not take a double dose or extra dose.

4. Notes:

1) Before initiating treatment with sparsentane, patients should discontinue angiotensin receptor blockers, endothelin receptor antagonists (ERA), and aliskiren to avoid possible drug interactions.

2) During treatment, patients should undergo regular liver function tests to ensure the safety of the drug on the liver.

3) Because sparsentane may affect the health of the fetus, women of childbearing potential should take a pregnancy test before starting treatment, and take a pregnancy test once a month during treatment and within one month after stopping treatment.

In summary, sparsentane serves as a novel treatment for primary idiopathic diseasesFor IgA nephropathy drugs, their clear indications and correct medication methods are crucial to ensure therapeutic efficacy and patient safety. Patients should strictly follow the doctor's advice, take the medicine on time and in the right amount, and pay attention to various precautions during medication. At present, Sparsentan is not yet available in China, so it cannot be purchased directly in the country. Patients in need may consider consulting professional overseas medical service agencies.